High G3BP1 levels are associated with a poor prognosis in patients with BLCA treated with anti‐PD‐L1 antibody; thus, the use of EGCG may also enhance the efficacy of ICIs in human BLCA. The gene discussed is CD274; the disease is bladder transitional cell carcinoma.